Xi I Chen

US Patent:

6426347, Jul 30, 2002

Filed:

Dec 13, 2000

Appl. No.:

09/736566

Inventors:

Andrew Thurkauf - Danbury CT
Xi Chen - Clinton CT

Assignee:

Neurogen Corporation - Branford CT

International Classification:

C07D295073

US Classification:

51425503, 544392

Abstract:

Disclosed are compounds of the formula: or the pharmaceutically acceptable addition salts thereof wherein: R is halogen or C -C alkyl; and R and R are the same or different and represent hydrogen, halogen, C -C alkyl, C -C alkoxy, alkylthio, hydroxy, amino, mono(C -C )alkylamino, di(C -C )alkylamino, or R and R together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

US Patent:

6429312, Aug 6, 2002

Filed:

Mar 19, 2001

Appl. No.:

09/812199

Inventors:

Jun Yuan - Clinton CT
Xi Chen - New Haven CT

Assignee:

Neurogen Corporation - Branford CT

International Classification:

C07D40914

US Classification:

544295, 544363, 544364, 544375, 544376, 544333, 5462811, 546146, 546175, 546194, 546202, 546256, 549 43, 549 48

Abstract:

Disclosed are compounds of the formula: or the pharmaceutically acceptable acid addition salts thereof, wherein: R , R , R , R are the same or different and represent hydrogen, C -C alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C -C alkoxy, âO CRâ, âNHCORâ, âCORâ, âSO Râ, where Râ is C -C alkyl and wherein m is 0, 1 or 2; or R , R , R , R independently represent âCONRâRâ, or âNRâRâ where Râ and Râ independently represent hydrogen or C -C alkyl; R is hydrogen or C -C alkyl; and R represents an aminoalkyl group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimers disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

US Patent:

6656943, Dec 2, 2003

Filed:

Jun 28, 2002

Appl. No.:

10/186235

Inventors:

Andrew Thurkauf - Danbury CT
Xi Chen - Clinton CT

Assignee:

Neurogen Corporation - Branford CT

International Classification:

A61K 31495

US Classification:

51425503, 544392

Abstract:

Disclosed are compounds of the formula: or the pharmaceutically acceptable addition salts thereof wherein: R is halogen or C -C alkyl; and R and R are the same or different and represent hydrogen, halogen, C -C alkyl, C -C alkoxy, alkylthio, hydroxy, amino, mono(C -C )alkylamino, di(C -C )alkylamino, or R and R together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

US Patent:

7101887, Sep 5, 2006

Filed:

Jun 27, 2005

Appl. No.:

11/167735

Inventors:

Andrew Thurkauf - Danbury CT, US
Xi Chen - Clinton CT, US

Assignee:

Neurogen Corporation - Branford CT

International Classification:

A61K 31/495
C07D 295/076

US Classification:

51425503, 544392

Abstract:

Disclosed are compounds of the formula:.

US Patent:

7183300, Feb 27, 2007

Filed:

Nov 10, 2005

Appl. No.:

11/271437

Inventors:

Michael F. Summers - Ellicott City MD, US
Atul Agarwal - Hamden CT, US
Xi Chen - Killingworth CT, US
Milind Deshpande - Madison CT, US

International Classification:

A61K 31/4245
A61K 31/426
A61K 31/341
C07D 271/08
C07D 277/48
C07D 307/54

US Classification:

514364, 514377, 514461, 548125, 548196, 549473

Abstract:

Substituted aryl aminomethyl thiazole ureas and analogues thereof that act as inhibitors of viral capsid formation, including HIV capsid formation, are provided here. Generally the virus capsid formation inhibitors described herein are compounds of Formula I.

US Patent:

7230159, Jun 12, 2007

Filed:

Mar 5, 2003

Appl. No.:

10/505744

Inventors:

Tesfaye Mengiste - West Lafayette IN, US
Xi Chen - Research Triangle Park NC, US
John Salmeron - Research Triangle Park NC, US
Robert Dietrich - Research Triangle Park NC, US

Assignee:

Syngenta Participations AG - Basel

International Classification:

C12N 15/82
C12N 15/09
A01H 5/00

US Classification:

800279, 800278, 800298, 536 241, 4353201, 435468

Abstract:

The present invention pertains to an isolated promoter sequence from BOSI gene encoding a protein for biotic and abiotic stress tolerance. Also, the invention relates to recombinant vectors, expression cassettes, host cells, plants or progeny thereof comprising nucleic acid molecules operably linked to said promoter.

US Patent:

20040083447, Apr 29, 2004

Filed:

Sep 22, 2003

Appl. No.:

10/667821

Inventors:

Andrew Thurkauf - Danbury CT, US
Xi Chen - Clinton CT, US

Assignee:

Neurogen Corporation, A Corporation of the State of Delaware - Branford CT

International Classification:

G06F009/44

US Classification:

717/100000, 717/105000

Abstract:

Disclosed are compounds of the formula: or the pharmaceutically acceptable addition salts thereof wherein: Ris halogen or C-Calkyl; and Rand Rare the same or different and represent hydrogen, halogen, C-Calkyl, C-Calkoxy, alkylthio, hydroxy, amino, mono(C-C)alkylamino, di(C-C)alkylamino, or Rand Rtogether represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

US Patent:

20060100225, May 11, 2006

Filed:

Mar 23, 2005

Appl. No.:

11/088276

Inventors:

Xi Chen - Killingworth CT, US
Andrew Thurkauf - Ridgefield CT, US
Shirley Louise-May - Guilford CT, US

International Classification:

A61K 31/513
A61K 31/505
C07D 239/32

US Classification:

514269000, 514275000, 544320000, 544330000

Abstract:

Compounds of Formula 1, and pharmaceutically acceptable forms thereof, are provided: wherein the variables X, Y, Z, A, R, R, R, Rand Rare defined herein. Certain compounds of Formula 1 described herein which possess potent antiviral activity. Certain compounds of Formula 1 that are potent and/or selective inhibitors of Hepatitis C virus replication. Pharmaceutical compositions containing one or more compounds of Formula 1, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are also provided. Methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula 1 effective to reduce signs or symptoms of the disease or disorder are disclosed. These infectious diseases include viral infections, particularly HCV infections. Methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula 1 as a single active agent or administering a compound of Formula 1 in combination with on or more other therapeutic agent.